Abstract:In the past decades, reconstituted high density lipoprotein (rHDL) has been successfully developed as a drug carrier since the enhanced HDL-lipids uptake is demonstrated in several human cancers. In this paper, rHDL, for the first time, was utilized to co-encapsulate two hydrophobic drugs: an anticancer drug, paclitaxel (PTX), and a new reversal agent for P-gp (P-glycoprotein)-mediated multidrug resistance (MDR) of cancer, N-cyano-1-[(3,4-dimethoxyphenyl)methyl]-3,4-dihydro-6,7-dimethoxy-N′-octyl-2(1H)-isoquinoline-carboximidamide (HZ08). We proposed this drug co-delivery strategy to reverse PTX resistance. The study aimed to develop a biomimetic nanovector, reconstituted high density lipoprotein (rHDL), mediating targeted PTX-HZ08 delivery for cancer therapy. Using sodium cholate dialysis method, we successfully formulated dual-agent co-delivering rHDL nanoparticles (PTX-HZ08-rHDL NPs) with a typical spherical morphology, well-distributed size (~100nm), high drug encapsulation efficiency (approximately 90%), sustained drug release properties and exceptional stability even after storage for 1month or incubation in 10% fetal bovine serum (FBS) DMEM for up to 2days. Results demonstrated that PTX-HZ08-rHDL NPs significantly enhanced anticancer efficacy in vitro, including higher cytotoxicity and better ability to induce cell apoptosis against both PTX-sensitive and -resistant MCF-7 human breast cancer cell lines (MCF-7 and MCF-7/PTX cells). Mechanism studies demonstrated that these improvements could be correlated with increased cellular uptake of PTX mediated by scavenger receptor class B type I (SR-BI) as well as prolonged intracellular retention of PTX due to the HZ08 mediated drug-efflux inhibition. In addition, in vivo investigation showed that the PTX-HZ08-rHDL NPs were substantially safer, have higher tumor-targeted capacity and have stronger antitumor activity than the corresponding dosage of paclitaxel injection. These findings suggested that rHDL NPs could be an ideal tumor-targeted nanovector for simultaneous transfer of insoluble anticancer drug and drug resistance reversal agents. The PTX-HZ08-rHDL NPs co-delivery system might be a new promising strategy to overcome tumor drug resistance.

Reconstituted High Density Lipoprotein Mediated Targeted Co-Delivery of HZ08 and Paclitaxel Enhances the Efficacy of Paclitaxel in Multidrug-Resistant MCF-7 Breast Cancer Cells.

Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin

Reversal of Multidrug Resistance by Co-Delivery of Paclitaxel and Lonidamine Using a TPGS and Hyaluronic Acid Dual-Functionalized Liposome for Cancer Treatment

Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion

Natural Particulates Inspired Specific-Targeted Codelivery of Sirna and Paclitaxel for Collaborative Antitumor Therapy

Ratiometric Co-Encapsulation and Co-Delivery of Doxorubicin and Paclitaxel by Tumor-Targeted Lipodisks for Combination Therapy of Breast Cancer

Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells

Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier.

Lysosome-Independent Intracellular Drug/Gene Codelivery by Lipoprotein-Derived Nanovector for Synergistic Apoptosis-Inducing Cancer-Targeted Therapy

Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.

Systematic Evaluation of Multifunctional Paclitaxel-Loaded Polymeric Mixed Micelles As a Potential Anticancer Remedy to Overcome Multidrug Resistance.

Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles

Overcoming drug-resistant lung cancer by paclitaxel-loaded hyaluronic acid-coated liposomes targeted to mitochondria.

Low-density Lipoprotein-Coupled Micelles with Reduction and Ph Dual Sensitivity for Intelligent Co-Delivery of Paclitaxel and Sirna to Breast Tumor

Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor

The Anticancer Efficacy of Paclitaxel Liposomes Modified with Low-Toxicity Hydrophobic Cell-Penetrating Peptides in Breast Cancer: an in Vitro and in Vivo Evaluation

Enhanced Anticancer Efficacy of Paclitaxel Through Multistage Tumor-Targeting Liposomes Modified with RGD and KLA Peptides

Lipoprotein-mimicking nanotherapeutics reconstituted with chenodeoxycholic acid modified protein for efficient tumor?targeting

Ratiometric co-delivery of doxorubicin and paclitaxel prodrug by remote-loading liposomes for the treatment of triple-negative breast cancer

Dual Targeting Biomimetic Liposomes for Paclitaxel/DNA Combination Cancer Treatment

Reduction-sensitive Dual Functional Nanomicelles for Improved Delivery of Paclitaxel.